Page 140 - Q26 -

¥ÿ≈æ“À

treatment could not be reached out by most of those living with HIV around

the globe. In entry of generic medicines in the market generally brought about
abrupt reduction of prices, so that today HIV treatment can be accommodated
(1)
not more over USD $75 per individual a year. This experience has led to the

increasing realization that rigid patent protection applicable to medicines can
threatens accessibility to pharmaceutical and derogates the fundamental

human rights to health. For example, in Thailand, generic drugs play a key

role in ensuring accessibility of Thai people to medicines and lessening the

expenditure on them since the prices of generic drugs are generally much

lower than brand-name drugs. The research on the affordability of a
Hydrochlorothiazide, Enalapril, Glibenclamide and Amoxicillin sold to the

private sector in Thailand shows that the lowest-paid government employees

(with the wages of 211.5 baht per day) will need to work around 0.98 days
(207 baht) to have the ability to afford these medicines; in contrast, the same

employees will need to work approximately 4.17 days (881 baht) to be able

(2)
to obtain these drugs.

Some scholars argue that, in fact, stringent patent protection in

developing countries will not lead to significant counterbalancing benefits from

inventions since developing countries are comprised of a limited number of

(1)
World Health Organisation (WHO),†Commission on Intellectual Property Rights, Innovation.
and Public Health, Public Health, Innovation and Intellectual Property Rights: Report of the
Commission on Intellectual Property Rights, Innovation and Public Health (2006).
(2)
Cha-oncin Sooksriwong, çMedicine Prices in Thailand: A Result of No Medicine Pricing
Policy,é†Southern Med Review†2, no. 2 (2009): 13.

¡°√“§¡ - ‡¡…“¬π ÚıˆÛ 129